US Broker Ratings

Fortrea Holdings Inc. (FTRE) Stock Analysis: Navigating Volatility and Strategic Collaborations in the Biotech Sector

Fortrea Holdings Inc. (FTRE), a prominent player in the biotechnology industry, has been capturing the attention of investors with its strategic initiatives and volatile stock performance. Headquartered in Durham, North..

Personalis, Inc. (PSNL) Stock Analysis: Navigating a Complex Landscape with a Strong Buy Consensus

Personalis, Inc. (NASDAQ: PSNL), a prominent player in the healthcare sector, specializes in advanced cancer genomic tests and services. Despite facing significant challenges, including negative revenue growth and a heavy..

Surmodics, Inc. (SRDX) Investor Outlook: Navigating Challenges and Opportunities in the Medical Device Sector

Surmodics, Inc. (NASDAQ: SRDX), a key player in the healthcare sector specializing in medical devices, finds itself at a critical juncture. With a market capitalization of $393.18 million, Surmodics offers..

Rapport Therapeutics, Inc. (RAPP) Stock Analysis: Unpacking a 97% Potential Upside

Rapport Therapeutics, Inc. (NASDAQ: RAPP) is capturing investor attention with its promising advancements in the biotechnology sector, specifically targeting central nervous system (CNS) disorders. With a compelling market cap of..

Kamada Ltd. (KMDA) Stock Analysis: Exploring a 104% Potential Upside in the Healthcare Sector

Kamada Ltd. (NASDAQ: KMDA), an Israel-based healthcare company specializing in plasma-derived protein therapeutics, stands in a unique position within the drug manufacturing industry. With a market capitalization of $393.91 million,..

LENZ Therapeutics, Inc. (LENZ) Stock Analysis: A Biotech with a 72.88% Upside Potential

LENZ Therapeutics, Inc. (LENZ), a promising player in the biotechnology sector, is capturing investor attention with its focus on innovative therapies to enhance vision. Headquartered in Solana Beach, California, LENZ..

Septerna, Inc. (SEPN) Stock Analysis: Biotechnology Innovator with 11.29% Potential Upside

Septerna, Inc. (NASDAQ: SEPN) is capturing the attention of investors in the healthcare sector, particularly within the biotechnology industry. With a market capitalization of $971.51 million, this South San Francisco-based..

Tourmaline Bio, Inc. (TRML) Stock Analysis: Navigating the Biotech Landscape with a Steady Valuation

Tourmaline Bio, Inc. (NASDAQ: TRML), a dynamic player in the biotechnology sector, stands out with its niche focus on developing treatments for immune and inflammatory diseases. Headquartered in New York..

Tilray Brands, Inc. (TLRY) Stock Analysis: Navigating a 20% Potential Upside in the Cannabis Market

For investors interested in the evolving cannabis market, Tilray Brands, Inc. (NASDAQ: TLRY) presents an intriguing opportunity with a potential upside of 20.50%. This Canadian-based company, with a market capitalization..

AngioDynamics, Inc. (ANGO) Stock Analysis: Exploring a 54% Potential Upside Amid Healthcare Innovation

AngioDynamics, Inc. (NASDAQ: ANGO), a notable player in the healthcare sector, is capturing investor attention with a compelling potential upside of 54.17%. As a specialist in medical instruments and supplies,..

Emergent BioSolutions Inc. (EBS) Stock Analysis: Exploring a 39.75% Upside Potential for Investors

Emergent BioSolutions Inc. (NYSE: EBS), a prominent player in the healthcare sector, has captured investor attention with its diverse portfolio of preparedness and response solutions for public health threats. Operating..

Myriad Genetics, Inc. (MYGN) Stock Analysis: Navigating Challenges with Strategic Alliances in Healthcare

Investors with an eye on the healthcare sector may find Myriad Genetics, Inc. (NASDAQ: MYGN) worth a deeper look. The company, based in Salt Lake City, Utah, specializes in molecular..

Treace Medical Concepts, Inc. (TMCI) Stock Analysis: Evaluating a Potential 23.96% Upside in the Medical Devices Sector

Treace Medical Concepts, Inc. (NASDAQ: TMCI) stands out in the medical devices industry with a promising potential upside of 23.96%, making it a noteworthy candidate for investors seeking growth in..

Castle Biosciences, Inc. (CSTL) Stock Analysis: 47% Potential Upside Beckons Investors

Castle Biosciences, Inc. (NASDAQ: CSTL) is capturing investor attention with a compelling 47% potential upside based on its average target price. As a key player in the healthcare sector, specializing..

Semler Scientific, Inc. (SMLR) Stock Analysis: Exploring a 230.99% Potential Upside in the Medical Devices Sector

Semler Scientific, Inc. (NASDAQ: SMLR), a prominent player in the healthcare sector, particularly within the medical devices industry, is capturing investor attention with a striking potential upside of 230.99%. With..

Owens & Minor, Inc. (OMI) Stock Analysis: Exploring a Potential 19.45% Upside in the Healthcare Sector

Owens & Minor, Inc. (NYSE: OMI) stands as a significant player in the healthcare sector, specifically within medical distribution. With a market capitalization of $406.3 million, this Glen Allen, Virginia-based..

SIGA Technologies Inc. (SIGA) Stock Analysis: Impressive Revenue Growth Amidst Healthcare Sector Dynamics

Investors looking to explore opportunities within the healthcare sector should pay close attention to SIGA Technologies Inc. (NASDAQ: SIGA). This commercial-stage pharmaceutical company, headquartered in New York, focuses on the..

ArriVent BioPharma, Inc. (AVBP) Stock Analysis: Unveiling a Huge 118% Potential Upside in Biotech

ArriVent BioPharma, Inc. (NASDAQ: AVBP) is capturing attention in the biotechnology sector, not only for its innovative approach to tackling cancer but also for the impressive potential upside its stock..

Kura Oncology, Inc. (KURA) Stock Analysis: Unveiling a 196.70% Potential Upside in Biotechnology

Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company, is capturing attention with its impressive projected upside of nearly 196.70%. Specializing in developing treatments for cancer, particularly acute leukemias and..

Oculis Holding AG (OCS) Stock Analysis: A Biotech Gem with a 100% Upside Potential

Oculis Holding AG (OCS), a Switzerland-based biopharmaceutical company, has caught the attention of investors with its promising portfolio in ophthalmic drug development. Operating within the healthcare sector and more specifically..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds